~~WHAT IS CLAIMED IS:~~

1. An aqueous composition of matter comprising an antibody and an alkylglycoside having a CMC value of about 1.0 mM or greater in water at 25°C.

2. The composition of matter of Claim 1, wherein the antibody is a monoclonal antibody.

3. The composition of matter of Claim 1, wherein the alkylglycoside is selected from the group consisting of n-hexyl-β-D-glucopyranoside, n-heptyl-β-D-glucopyranoside, n-octyl-β-D-glucopyranoside, n-nonyl-β-D-glucopyranoside, n-decyl-β-D-glucopyranoside, 3-cyclohexyl-1-propyl-β-D-glucoside, 3-cyclohexyl-1-butyl-β-D-glucoside, n-hexyl-β-D-maltopyranoside, n-octyl-β-D-maltopyranoside, n-nonyl-β-D-maltopyranoside, n-decyl-β-D-maltopyranoside, cyclohexyl-methyl-β-D-maltoside, 2-cyclohexyl-ethyl-β-D-maltoside, 3-cyclohexyl-propyl-β-D-maltoside, 4-cyclohexyl-butyl-β-D-maltoside, and 5-cyclohexyl-pentyl-β-D-maltoside.

4. The composition of matter of Claim 1, wherein the alkylglycoside is n-octyl-β-D-glucopyranoside.

5. The composition of matter of Claim 1, wherein the alkylglycoside is n-decyl-β-D-glucopyranoside.

6. The composition of matter of Claim 1, wherein the alkylglycoside is n-decyl-β-D-maltopyranoside.

7. The composition of matter of Claim 1, wherein the alkylglycoside is n-hexyl-β-D-glucopyranoside.

8. The composition of matter of Claim 1 comprising an agitation-induced aggregation inhibiting amount of said alkylglycoside.

9. The composition of matter of Claim 1 comprising an oxidation preventing amount of said alkylglycoside.

10. The composition of matter of Claim 1, wherein the alkylglycoside is present at a concentration that is lower than the CMC value of the alkylglycoside in water at 25°C.

11. The composition of matter of Claim 1 which is stable at a temperature of about 2-8°C for at least one year.

12. The composition of matter of Claim 1 which is stable at a temperature of about 30°C for at least one month.

13. The composition of matter of Claim 1 which is not lyophilized and is not subjected to prior lyophilization.

14. The composition of matter of Claim 1 which is a reconstituted lyophilized formulation.

15. The composition of matter of Claim 1, wherein the antibody is susceptible to aggregation.

16. The composition of matter of Claim 1, wherein the antibody is susceptible to oxidation.

17. A method of inhibiting agitation-induced aggregation of an antibody present in an first aqueous solution, said method comprising the step of adding to said first aqueous solution an agitation-induced aggregation inhibiting amount of an alkylglycoside having a CMC value of about 1.0 mM or greater in water at 25°C, thereby providing a second aqueous solution.

18. The method of Claim 17, wherein the antibody is a monoclonal antibody.

19. The method of Claim 17, wherein the alkylglycoside is selected from the group consisting of n-hexyl-β-D-glucopyranoside, n-heptyl-β-D-glucopyranoside, n-octyl-β-D-glucopyranoside, n-nonyl-β-D-glucopyranoside, n-decyl-β-D-glucopyranoside, 3-cyclohexyl-1-propyl-β-D-glucoside, 3-cyclohexyl-1-butyl-β-D-glucoside, n-hexyl-β-D-maltopyranoside, n-octyl-β-D-maltopyranoside, n-nonyl-β-D-maltopyranoside, n-decyl-β-D-maltopyranoside, cyclohexyl-methyl-β-D-maltoside, 2-cyclohexyl-ethyl-β-D-maltoside, 3-cyclohexyl-propyl-β-D-maltoside, 4-cyclohexyl-butyl-β-D-maltoside, and 5-cyclohexyl-pentyl-β-D-maltoside.

20. The method of Claim 17, wherein the alkylglycoside is n-octyl-β-D-glucopyranoside.

21. The method of Claim 17, wherein the alkylglycoside is n-decyl-β-D-glucopyranoside.

22. The method of Claim 17, wherein the alkylglycoside is n-decyl-β-D-maltopyranoside.

23. The method of Claim 17, wherein the alkylglycoside is n-hexyl-β-D-glucopyranoside.

24. The method of Claim 17, wherein the alkylglycoside is added to a final concentration that is lower than the CMC value of the alkylglycoside in water at 25°C.

25. The method of Claim 17, comprising the further step of lyophilizing said second aqueous solution.

26. A method of preventing the oxidation of an antibody present in an first aqueous solution, said method comprising the step of adding to said first aqueous solution an oxidation preventing amount of an alkylglycoside having a CMC value of about 1.0 mM or greater in water at 25°C, thereby providing a second aqueous solution.

27. The method of Claim 26, wherein the antibody is a monoclonal antibody.

28. The method of Claim 26, wherein the alkylglycoside is selected from the group consisting of n-hexyl-β-D-glucopyranoside, n-heptyl-β-D-glucopyranoside, n-octyl-β-D-glucopyranoside, n-nonyl-β-D-glucopyranoside, n-decyl-β-D-glucopyranoside, 3-cyclohexyl-1-propyl-β-D-glucoside, 3-cyclohexyl-1-butyl-β-D-glucoside, n-hexyl-β-D-maltopyranoside, n-octyl-β-D-maltopyranoside, n-nonyl-β-D-maltopyranoside, n-decyl-β-D-maltopyranoside, cyclohexyl-methyl-β-D-maltoside, 2-cyclohexyl-ethyl-β-D-maltoside, 3-cyclohexyl-propyl-β-D-maltoside, 4-cyclohexyl-butyl-β-D-maltoside, and 5-cyclohexyl-pentyl-β-D-maltoside.

29. The method of Claim 26, wherein the alkylglycoside is n-octyl-β-D-glucopyranoside.

30. The method of Claim 26, wherein the alkylglycoside is n-decyl-β-D-glucopyranoside.

31. The method of Claim 26, wherein the alkylglycoside is n-decyl-β-D-maltopyranoside.

32. The method of Claim 26, wherein the alkylglycoside is n-hexyl-β-D-glucopyranoside.

33. The method of Claim 26, wherein the alkylglycoside is added to a final concentration that is lower than the CMC value of the alkylglycoside in water at 25°C.

34. The method of Claim 26, wherein the alkylglycoside is added to a final concentration that is higher than the CMC value of the alkylglycoside in water at 25°C.

35. The method of Claim 26, comprising the further step of lyophilizing said second aqueous solution.

36. The method of Claim 26, wherein said oxidation is light-induced oxidation.

37. The method of Claim 36, wherein said light-induced oxidation is of tryptophan residues in said antibody.

WHAT IS CLAIMED IS:

1. An aqueous composition of matter comprising an antibody and an alkylglycoside having a CMC value of about 1.0 mM or greater in water at 25°C, wherein the alkylglycoside is present at a concentration that is lower than the CMC value of the alkylglycoside in water at 25°C.

2. The composition of matter of Claim 1, wherein the antibody is a monoclonal antibody.

3. The composition of matter of Claim 1, wherein the alkylglycoside is selected from the group consisting of n-hexyl-β-D-glucopyranoside, n-heptyl-β-D-glucopyranoside, n-octyl-β-D-glucopyranoside, n-nonyl-β-D-glucopyranoside, n-decyl-β-D-glucopyranoside, 3-cyclohexyl-1-propyl-β-D-glucoside, 3-cyclohexyl-1-butyl-β-D-glucoside, n-hexyl-β-D-maltopyranoside, n-octyl-β-D-maltopyranoside, n-nonyl-β-D-maltopyranoside, n-decyl-β-D-maltopyranoside, cyclohexyl-methyl-β-D-maltoside, 2-cyclohexyl-ethyl-β-D-maltoside, 3-cyclohexyl-propyl-β-D-maltoside, 4-cyclohexyl-butyl-β-D-maltoside, and 5-cyclohexyl-pentyl-β-D-maltoside.

4. The composition of matter of Claim 1, wherein the alkylglycoside is n-octyl-β-D-glucopyranoside.

5. The composition of matter of Claim 1, wherein the alkylglycoside is n-decyl-β-D-glucopyranoside.

6. The composition of matter of Claim 1, wherein the alkylglycoside is n-decyl-β-D-maltopyranoside.

7. The composition of matter of Claim 1, wherein the alkylglycoside is n-hexyl-β-D-glucopyranoside.

8. The composition of matter of Claim 1 comprising an agitation-induced aggregation inhibiting amount of said alkylglycoside.

9. The composition of matter of Claim 1 comprising an oxidation preventing amount of said alkylglycoside.

10. The composition of matter of Claim 1 which is stable at a temperature of about 2-8°C for at least one year.

11. The composition of matter of Claim 1 which is stable at a temperature of about 30°C for at least one month.

12. The composition of matter of Claim 1 which is not lyophilized and is not subjected to prior lyophilization.

13. The composition of matter of Claim 1 which is a reconstituted lyophilized formulation.

14. The composition of matter of Claim 1, wherein the antibody is susceptible to aggregation.

15. The composition of matter of Claim 1, wherein the antibody is susceptible to oxidation.

16. A method of inhibiting agitation-induced aggregation of an antibody present in an first aqueous solution, said method comprising the step of adding to said first aqueous solution an agitation-induced aggregation inhibiting amount of an alkylglycoside having a CMC value of about 1.0 mM or greater in water at 25°C, wherein the alkylglycoside is added to a final concentration that is lower than the CMC value of the alkylglycoside in water at 25°C, thereby providing a second aqueous solution.

17. The method of Claim 16, wherein the antibody is a monoclonal antibody.

18. The method of Claim 16, wherein the alkylglycoside is selected from the group consisting of n-hexyl-β-D-glucopyranoside, n-heptyl-β-D-glucopyranoside, n-octyl-β-D-glucopyranoside, n-nonyl-β-D-glucopyranoside, n-decyl-β-D-glucopyranoside, 3-cyclohexyl-1-propyl-β-D-glucoside, 3-cyclohexyl-1-butyl-β-D-glucoside, n-hexyl-β-D-maltopyranoside, n-octyl-β-D-maltopyranoside, n-nonyl-β-D-maltopyranoside, n-decyl-β-D-maltopyranoside, cyclohexyl-methyl-β-D-maltoside, 2-cyclohexyl-ethyl-β-D-maltoside, 3-cyclohexyl-propyl-β-D-maltoside, 4-cyclohexyl-butyl-β-D-maltoside, and 5-cyclohexyl-pentyl-β-D-maltoside.

19. The method of Claim 16, wherein the alkylglycoside is n-octyl-β-D-glucopyranoside.

20. The method of Claim 16, wherein the alkylglycoside is n-decyl-β-D-glucopyranoside.

21. The method of Claim 16, wherein the alkylglycoside is n-decyl-β-D-maltopyranoside.

22. The method of Claim 16, wherein the alkylglycoside is n-hexyl-β-D-glucopyranoside.

23. The method of Claim 16, comprising the further step of lyophilizing said second aqueous solution.

24. A method of preventing oxidation of an antibody present in an first aqueous solution, said method comprising the step of adding to said first aqueous solution an oxidation preventing amount of an alkylglycoside having a CMC value of about 1.0 mM or greater in water at 25°C, wherein the alkylglycoside is added to a final concentration that is lower than the CMC value of the alkylglycoside in water at 25°C, thereby providing a second aqueous solution.

25. The method of Claim 24, wherein the antibody is a monoclonal antibody.

26. The method of Claim 24, wherein the alkylglycoside is selected from the group consisting of n-hexyl-β-D-glucopyranoside, n-heptyl-β-D-glucopyranoside, n-octyl-β-D-

glucopyranoside, n-nonyl-β-D-glucopyranoside, n-decyl-β-D-glucopyranoside, 3-cyclohexyl-1-propyl-β-D-glucoside, 3-cyclohexyl-1-butyl-β-D-glucoside, n-hexyl-β-D-maltopyranoside, n-octyl-β-D-maltopyranoside, n-nonyl-β-D-maltopyranoside, n-decyl-β-D-maltopyranoside, cyclohexyl-methyl-β-D-maltoside, 2-cyclohexyl-ethyl-β-D-maltoside, 3-cyclohexyl-propyl-β-D-maltoside, 4-cyclohexyl-butyl-β-D-maltoside, and 5-cyclohexyl-pentyl-β-D-maltoside.

27. The method of Claim 24, wherein the alkylglycoside is n-octyl-β-D-glucopyranoside.

28. The method of Claim 24, wherein the alkylglycoside is n-decyl-β-D-glucopyranoside.

29. The method of Claim 24, wherein the alkylglycoside is n-decyl-β-D-maltopyranoside.

30. The method of Claim 24, wherein the alkylglycoside is n-hexyl-β-D-glucopyranoside.

31. The method of Claim 24, comprising the further step of lyophilizing said second aqueous solution.

32. The method of claim 24, wherein said oxidation is light-induced oxidation.

33. The method of Claim 32, wherein said light-induced oxidation is of tryptophan residues in said antibody.